BSc FRCPath - INmune Bio Chief Officer
| INMB Stock | USD 4.87 0.11 2.31% |
Insider
BSc FRCPath is Chief Officer of INmune Bio
| Age | 59 |
| Address | 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432 |
| Phone | 858 964 3720 |
| Web | https://www.inmunebio.com |
INmune Bio Management Efficiency
The company has return on total asset (ROA) of (0.4497) % which means that it has lost $0.4497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9896) %, meaning that it created substantial loss on money invested by shareholders. INmune Bio's management efficiency ratios could be used to measure how well INmune Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.78. The current year's Return On Capital Employed is expected to grow to -0.73. At present, INmune Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.56, whereas Total Assets are forecasted to decline to about 41.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ramtin MD | RenovoRx | 58 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Lori CPA | Lumos Pharma | 40 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Jeff York | Seres Therapeutics | N/A | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Hing Wong | HCW Biologics | 70 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Carl Langren | Lumos Pharma | 69 | |
| BBA CPA | Lumos Pharma | 57 | |
| James Ahlers | RenovoRx | 60 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| James JD | Eliem Therapeutics | 58 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Lisa Miller | Lumos Pharma | N/A | |
| Ronald CPA | RenovoRx | N/A | |
Management Performance
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.45 |
INmune Bio Leadership Team
Elected by the shareholders, the INmune Bio's board of directors comprises two types of representatives: INmune Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of INmune. The board's role is to monitor INmune Bio's management team and ensure that shareholders' interests are well served. INmune Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, INmune Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Barnum, Head Neuroscience | ||
| BSc FRCPath, Chief Officer | ||
| Raymond MD, President, CoFounder | ||
| Joshua Esq, General Counsel | ||
| David MBA, Treasurer CFO |
INmune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is INmune Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (989.21) % | ||||
| Current Valuation | 77.34 M | ||||
| Shares Outstanding | 22.17 M | ||||
| Shares Owned By Insiders | 28.72 % | ||||
| Shares Owned By Institutions | 24.25 % | ||||
| Number Of Shares Shorted | 3.48 M | ||||
| Price To Earning | (7.51) X | ||||
| Price To Book | 2.79 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.63) | Return On Assets (0.45) | Return On Equity (0.99) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.